Welcome to our dedicated page for TIC news (Ticker: TIC), a resource for investors and traders seeking the latest updates and insights on TIC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TIC's position in the market.
Acuren reported financial results for Q3 and nine months ended September 30, 2024, showing improved performance. Q3 Combined Revenue increased 14.1% to $303.0 million, with Combined Adjusted EBITDA up 14.8% and margin at 16.9%. For the nine-month period, Combined Revenue grew 7.1% to $835.4 million, while Combined Adjusted EBITDA rose 15.2% with a margin of 17.5%.
The company completed the ASP Acuren Acquisition for $1.88 billion on July 30, 2024. Following its re-domiciliation from British Virgin Islands to Delaware, Acuren expects to begin trading on OTC Markets by year-end and plans to list on the NYSE in Q1 2025. The company maintains a strong balance sheet with over $130 million in cash.
Acuren has announced two significant developments: First, the SEC has declared effective its Registration Statement on Form S-4 (File No. 333-282976) as of December 16, 2024. Second, the company has completed its re-domiciliation from the British Virgin Islands to become a Delaware The company expects to begin trading on the OTC Market before year-end and plans to apply for NYSE listing in Q1 2025.
